SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

URSO, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.290
AS - Asia 3.961
EU - Europa 1.710
SA - Sud America 661
AF - Africa 128
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.761
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.083
SG - Singapore 1.490
IT - Italia 772
CN - Cina 597
BR - Brasile 506
VN - Vietnam 492
BD - Bangladesh 462
HK - Hong Kong 335
DE - Germania 204
GB - Regno Unito 130
JP - Giappone 129
FR - Francia 117
IN - India 101
CA - Canada 100
FI - Finlandia 79
RU - Federazione Russa 78
NL - Olanda 73
ID - Indonesia 72
MX - Messico 70
IQ - Iraq 46
AR - Argentina 42
PL - Polonia 40
AT - Austria 39
ZA - Sudafrica 38
TR - Turchia 34
ES - Italia 31
SE - Svezia 29
CO - Colombia 27
PK - Pakistan 26
VE - Venezuela 25
LT - Lituania 21
EC - Ecuador 20
UA - Ucraina 20
MA - Marocco 18
SA - Arabia Saudita 18
TN - Tunisia 18
IR - Iran 17
BE - Belgio 16
KR - Corea 15
PH - Filippine 15
CL - Cile 14
PY - Paraguay 14
UZ - Uzbekistan 14
EG - Egitto 12
MY - Malesia 12
CR - Costa Rica 11
IL - Israele 11
AE - Emirati Arabi Uniti 10
DZ - Algeria 10
TH - Thailandia 10
CZ - Repubblica Ceca 9
KE - Kenya 9
GR - Grecia 8
AZ - Azerbaigian 7
KG - Kirghizistan 7
PE - Perù 7
TT - Trinidad e Tobago 7
AU - Australia 6
TW - Taiwan 6
ET - Etiopia 5
RO - Romania 5
SN - Senegal 5
AO - Angola 4
CY - Cipro 4
HU - Ungheria 4
JM - Giamaica 4
JO - Giordania 4
QA - Qatar 4
RS - Serbia 4
BH - Bahrain 3
CH - Svizzera 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
IE - Irlanda 3
NI - Nicaragua 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AL - Albania 2
BO - Bolivia 2
DK - Danimarca 2
GE - Georgia 2
IS - Islanda 2
MK - Macedonia 2
NG - Nigeria 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TV - Tuvalu 2
AM - Armenia 1
BJ - Benin 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
Totale 10.739
Salva come PNG Salva come JPEG
Città #
Singapore 946
Ashburn 786
San Jose 583
Dallas 344
Hong Kong 331
Santa Clara 263
New York 220
Beijing 216
Los Angeles 180
Council Bluffs 154
Ho Chi Minh City 147
Hanoi 127
Tokyo 119
Chicago 82
Lauterbourg 80
Milan 68
Munich 68
Chandler 60
Buffalo 55
Rome 53
Bologna 51
Hefei 51
Jakarta 51
São Paulo 47
Orem 45
Atlanta 41
Ferrara 41
Frankfurt am Main 39
Mexico City 38
Shanghai 38
Lappeenranta 37
London 35
Warsaw 34
Houston 33
Brooklyn 31
Helsinki 29
Montreal 29
Toronto 28
Phoenix 26
The Dalles 26
Denver 25
Nuremberg 25
Haiphong 24
Da Nang 22
Chennai 21
Rio de Janeiro 21
Stockholm 21
Brasília 19
Fairfield 19
Johannesburg 19
Poplar 19
Salt Lake City 19
Amsterdam 17
Boston 17
Manchester 17
Naples 17
Baghdad 16
Falkenstein 16
Vienna 15
City of London 14
Moscow 14
Seattle 14
Bari 13
Istanbul 13
Mumbai 13
Tashkent 13
Turku 13
Dong Ket 12
Elk Grove Village 12
Wilmington 12
Asunción 11
Miami 11
Ottawa 11
Ankara 10
Boardman 10
Brussels 10
Medellín 10
Palermo 10
Porto Alegre 10
San Francisco 10
Tampa 10
Thái Nguyên 10
Kansas City 9
Nairobi 9
Parma 9
Turin 9
Assago 8
Belo Horizonte 8
Buriram 8
Cagliari 8
Dhaka 8
Hải Dương 8
San José 8
Caracas 7
Charlotte 7
Florence 7
Manaus 7
Monza 7
New Delhi 7
Paris 7
Totale 6.408
Salva come PNG Salva come JPEG
Nome #
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? 237
90 Y/177 Lu‐dotatoc From Preclinical Studies to Application in Humans 235
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 218
Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma 204
18F-FDG PET/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients 196
The Role of [68Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review 191
Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial 177
The Role of [18F]F-Choline PET/CT in the Initial Management and Outcome Prediction of Prostate Cancer: A Real-World Experience from a Multidisciplinary Approach 171
ML Models Built Using Clinical Parameters and Radiomic Features Extracted from 18F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer 170
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review—Part 1 oncological setting 170
MONTE CARLO SIMULATIONS IN RADIO-LIGAND THERAPY WITH LU-177 FOR NEUROENDOCRINE TUMOURS (NETS) 168
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study) 166
Relevance of Volumetric Parameters Applied to [68Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT 166
Is There a Role for FAPI PET in Urological Cancers? 163
99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications 163
Clinical-diagnostic relevance of breast “incidentaloma” detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: Correlation with radiological imaging and histopathology 159
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review– part 2 158
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer 157
PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature 156
Complicated Inguinal Hernia Incidentally Detected on a Radiolabelled Autologous White Blood Cell Scan 155
PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review 155
Rhenium Radioisotopes for Medicine, a Focus on Production and Applications 154
Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE 154
[18F]FDG PET-TC radiomics and machine learning in the evaluation of prostate incidental uptake 153
Positron Emission Tomography-Derived Radiomics and Artificial Intelligence in Multiple Myeloma: State-of-the-Art 150
18F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy 147
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives 146
Role of 18F-FDG PET/CT in evaluating lymph node status in patients with head and neck squamous cell carcinoma 145
Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study 143
68Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives 142
Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET) 142
Comparison of MRI vs. [18F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives 141
[18F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review 140
68Ga-PSMA-11 PET/CT in Bilateral Clear Cell Renal Cell Carcinoma: an Intra-patient Comparison Between High and Low Grade Tumors 139
Uncommon solitary nasal extramedullary plasmacytoma detected by 18F-FDG PET/CT 139
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score 138
Radioligand therapy in sympathetic-adrenal-medullary axis tumors: state of art and perspectives 138
Impact of Metastasis-directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT Study 138
FDG PET/CT Volume-Based Quantitative Data and Survival Analysis in Breast Cancer Patients: A Systematic Review of the Literature 132
Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer 131
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer 130
COMPARISON BETWEEN CLINICAL DOSIMETRIC PLATFORMS IN NET PATIENTS TREATED WITH PRRT 125
Artificial intelligence & nuclear medicine: an emerging partnership 123
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer 123
Diagnostic Accuracy of PET with 18F-Fluciclovine ([18F]FACBC) in Detecting High-Grade Gliomas: A Systematic Review and Meta-Analysis 122
The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness 122
Incidental findings of acute myeloid leukemia in Sjögren's syndrome detected by nuclear medicine techniques 121
Cavernous Hepatic Hemangioma at 18F‑Choline Positron Emission Tomography–Computed Tomography: Be Aware of the Pitfall 120
Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report 116
Insights into pet-based radiogenomics in oncology: an updated systematic review 115
18F-FDG PET/CT Radiomics for Predicting Therapy Response in Primary Mediastinal B-Cell Lymphoma: A Bi-Centric Pilot Study 115
Considerations on the preliminary results of the NETTER-2 trial: is the glass half full or half empty? 115
Safire CT iterative reconstruction protocol to reduce patient effective dose on PET/CT examinations 114
Misinterpretation of an inflammatory FDG uptake in a patient treated for Hodgkin lymphoma: a case report 112
18 F-Choline Versus 68 Ga-PSMA-11 PET/CT Imaging Comparison in Incidental Clear Cell Renal Cell Carcinoma 111
Superscan-Like Pattern on 18F-Choline PET/CT in a Patient With Essential Thrombocythemia 111
ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors 108
Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review 102
Radiomics Results for Adrenal Mass Characterization Are Stable and Reproducible Under Different Software 101
[99mTc]Tc-sestamibi for the differential diagnosis of renal masses: a study protocol 100
The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective 94
Extramedullary disease in multiple myeloma: what you might not expect on [18F]FDG PET/CT - a pictorial essay 93
Triple Tracer PET in Advanced Prostate Cancer: Chasing Phenotypic Plasticity 90
Lymphoid organs’ metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy: an exploratory study 88
One scan, many stories: deep learning for signal separation in multi-tracer PET imaging 84
Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000-2022) 82
PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality? 80
The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria 80
Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study 79
The Future Direction of Women in Nuclear Medicine and Nuclear Medicine in Women's Health 77
Clinical applications of long axial field-of-view PET/CT scanners in oncology 75
The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential 74
Molecular imaging of PARP in cancer: state-of-the-art 72
Phosphorus-32 microparticles for locally advanced pancreatic cancer: how and when? 71
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON? 70
Radioligand Therapy with Radiolabeled Somatostatin Analogues in Metastatic Bronchial Carcinoid: an Impressive Response 70
18 F-FDG PET/CT Volumetric Metabolic Parameters in the Staging of Head and Neck Squamous Cell Carcinoma 68
The Role of Molecular Imaging in Patients with Brain Metastases: A Literature Review 68
Synthetic imaging for research and education in nuclear medicine: Who’s afraid of the black box? 68
PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview 68
Radionuclide-based nanotechnologies in triple-negative breast cancer: current evidence and future perspectives 66
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting 65
Initial results of the use of a novel semiquantitative parameter in three-phase bone scan to predict 99mTc-HMPAO-labeled leukocyte scintigraphy in patients with unilateral total knee replacement 64
The expanding role of next-generation imaging in prostate cancer management: a cross-sectional survey exploring the clinical practice of uro-oncologists in North-Eastern Italy; on behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est) 63
Hepato-Biliary Imaging in an Acute Setting: Is There a Role for Nuclear Medicine? 62
AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy 59
Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights 55
Molecular Imaging Advances in Endometriosis: The Promise of Radiopharmaceuticals 54
Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach 52
Molecular Imaging in Cancer Chemoresistance: What’s Brewing? 42
The Value of FDG PET/CT in Penile Cancer: An Update 34
Real-world, multicenter assessment of 18 F-FDG PET/CT prognostic value in triple-negative breast cancer (TRINE-PET): the study protocol 25
Diagnostic accuracy of 18F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study 23
The future of nuclear medicine in Italy 23
Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms 17
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings 16
Illuminating Multiple Sclerosis: Next-Generation PET Tracers for Molecular Insights 12
The value of [18F]FDG PET/CT in fever of unknown origin (FUO): an update and future aspects 9
Editorial: Recent developments in artificial intelligence and radiomics 3
Totale 11.048
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.693
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.693
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202118 0 0 0 0 0 0 0 0 0 0 0 18
2021/202261 2 0 0 2 5 4 7 2 5 3 15 16
2022/2023186 7 15 3 17 21 20 18 18 14 2 42 9
2023/2024371 11 24 29 14 40 45 12 47 18 12 40 79
2024/20252.312 74 87 190 104 235 144 87 110 369 304 357 251
2025/20268.055 609 308 687 908 979 421 936 440 725 841 779 422
Totale 11.048